Stocksigma LogoStocksigma Logo

Supriya Lifescience Reports Q2 FY27 Results Amid Margin Contraction

Supriya Lifescience reported Q2 FY27 revenue of Rs 206.30 crore, up 3.2% YoY from Rs 199.83 crore. EBITDA dropped to Rs 45.40 crore from Rs 72.65 crore in

Supriya Lifescience Reports Q2 FY27 Results Amid Margin Contraction

Supriya Lifescience Ltd 路 Press Release 路 07 Nov 2026, 12:47 am

Supriya Lifescience Reports Q2 FY27 Results Amid Margin Contraction Supriya Lifescience reported Q2 FY27 revenue of Rs 206.30 crore, up 3.2% YoY from Rs 199.83 crore. EBITDA dropped to Rs 45.40 crore from Rs 72.65 crore in Q2 FY26, with EBITDA margin compressing to 22.0% from 36.4%. PAT fell to Rs 29.25 crore from Rs 50.43 crore, reflecting higher input costs, Ambernath facility ramp-up expenses, and LATAM regulatory shifts. H1 FY27 revenue reached Rs 396.04 crore, up 14.8% YoY. The company launched two anaesthetic products and scheduled an EU audit for Nov'26.

Original exchange filing (PDF)

More announcements from Supriya Lifescience Ltd

All Supriya Lifescience Ltd announcements